Prosecution Insights
Last updated: April 19, 2026
Application No. 17/795,515

Quinazoline compounds and the use thereof in the treatment of cancer

Final Rejection §102§103
Filed
Jul 26, 2022
Examiner
MCDOWELL, BRIAN E
Art Unit
1624
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Trobio Therapeutics Pty Ltd.
OA Round
2 (Final)
74%
Grant Probability
Favorable
3-4
OA Rounds
2y 4m
To Grant
99%
With Interview

Examiner Intelligence

Grants 74% — above average
74%
Career Allow Rate
818 granted / 1102 resolved
+14.2% vs TC avg
Strong +30% interview lift
Without
With
+30.3%
Interview Lift
resolved cases with interview
Typical timeline
2y 4m
Avg Prosecution
58 currently pending
Career history
1160
Total Applications
across all art units

Statute-Specific Performance

§101
1.0%
-39.0% vs TC avg
§103
15.0%
-25.0% vs TC avg
§102
19.5%
-20.5% vs TC avg
§112
47.6%
+7.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1102 resolved cases

Office Action

§102 §103
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Status of Claims Claims 1,11,13,18,38,47,56,61,66,78-80,83,87, and 91-93 are pending. Claims 47,56, 66,80,83,87, and 92 are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected invention, there being no allowable generic or linking claim. An action on the merits of claims 1,11,13,18,38,61,78-79,91 and 93 is contained herein. Information Disclosure Statement The examiner has considered the information disclosure statement filed most recently of record. Previous Objections/Rejections Any rejections or objections stated of record in the office action mailed on 10/21/2025 that are not explicitly addressed herein below, are hereby withdrawn in light of applicant's arguments and/or amendments filed 1/8/2026. Status of Rejections 35 USC § 112 (d) The rejection of claims 78-79 is maintained. Applicant’s arguments, see Remarks, filed 1/8/2026, with respect to the rejection set forth in the Non-Final Office Action mailed 10/21/2025, have been fully considered but are not found persuasive. To reiterate the rejection of record, claims 78-79 do not further limit claim 1 with respect to species bearing the following moiety for variable R1 wherein the group bears a heterocycle: PNG media_image1.png 88 218 media_image1.png Greyscale since claim 1 already sets forth that the variable must have a phenyl group. Applicant may cancel the claim(s), amend the claim(s) to place the claim(s) in proper dependent form, rewrite the claim(s) in independent form, or present a sufficient showing that the dependent claim(s) complies with the statutory requirements. Applicants argue that one skilled in the art recognizes that the group is a phenyl ring substituted with a methylenedioxy functional group which satisfies the definition of the claim wherein variable Y is alkoxy. The examiner respectfully disagrees. Claim 1 as written states that the phenyl group may be substituted with variable Y wherein Y may be selected from C1-C6alkoxy. The claims do not recite that two adjacent Y substituents may further form additional ring systems which falls under the scope of a methylenedioxy group. Thus, based on the most reasonable definition of the claims, the phenyl group described for variable R1 cannot be further fused to form additional ring systems and the rejection is maintained. New Rejections Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale or otherwise available to the public before the effective filing date of the claimed invention. Claims 1,11,13,18,38, 61, 78, 91, and 93 are rejected under 35 U.S.C. 102(a)(1) as being anticipated over PNG media_image2.png 16 358 media_image2.png Greyscale in STNext. STNext teach the following compound information: PNG media_image3.png 456 930 media_image3.png Greyscale wherein n = 1, Y = chloro, and R2 = C3alkylOH. Thus the claims are anticipated. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102 of this title, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claims 1,11,13,18,38,61,78-79,91, and 93 are rejected under 35 U.S.C. 103(a) as being unpatentable over over PNG media_image2.png 16 358 media_image2.png Greyscale in STNext. The instant claims may be drawn to the compound above described as PNG media_image2.png 16 358 media_image2.png Greyscale with the exception that the chloro group is replaced with a fluoro group. STN taught the compound described above. However a fluoro group and a chloro group are recognized in the art as halogens since they are part of the same group in the periodic table. Thus since they are both considered halogens the skilled artisan would have considered the two interchangeable and the resulting compounds obvious. Conclusion No claims are allowed. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to BRIAN E MCDOWELL whose telephone number is (571)270-5755. The examiner can normally be reached on 8:30-6 MF. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jeffrey Murray can be reached at 571-272-9023. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /BRIAN E MCDOWELL/Primary Examiner, Art Unit 1624
Read full office action

Prosecution Timeline

Jul 26, 2022
Application Filed
Oct 16, 2025
Non-Final Rejection — §102, §103
Jan 08, 2026
Response Filed
Mar 23, 2026
Final Rejection — §102, §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12599615
USE OF CAROTENOIDS IN THE TREATMENT OF SENESCENCE-RELATED DISEASES
2y 5m to grant Granted Apr 14, 2026
Patent 12604600
Organic Electroluminescent Element And Novel Iridium Complex
2y 5m to grant Granted Apr 14, 2026
Patent 12559494
NOVEL FUNCTIONALIZED LACTAMS AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE
2y 5m to grant Granted Feb 24, 2026
Patent 12552807
PCSK9 INHIBITORS AND METHODS OF USE THEREOF
2y 5m to grant Granted Feb 17, 2026
Patent 12545665
CRYSTAL FORM OF 6-(CYCLOPROPANECARBOXAMIDO)-4-((2-METHOXY-3-(1-METHYL-1H-1,2,4-TRIAZOL-3-YL)PHENYL)AMINO)-N-(METHYL-D3) PYRIDAZINE-3-CARBOXAMIDE
2y 5m to grant Granted Feb 10, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
74%
Grant Probability
99%
With Interview (+30.3%)
2y 4m
Median Time to Grant
Moderate
PTA Risk
Based on 1102 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month